Latest product unveiled as part of Dechra's campaign to support vets treating dogs with dermatological problems

Sporimune®, a new treatment to tackle atopic dermatitis in dogs, is being launched by Dechra Veterinary Products.

The easy dispensing, flexible dosing ciclosporin is licensed for the treatment of chronic manifestations of atopic dermatitis. It is the latest product unveiled as part of Dechra's campaign to support vets in general practice who regularly see significant numbers of dogs with dermatological problems.

Roger Brown, Senior Brand Manager at Dechra Veterinary Products, said: “Around 20 per cent of all small animal consultations involve skin conditions and canine atopic dermatitis can be challenging to diagnose and manage effectively.

“Although incurable, atopic dermatitis can be managed using a multimodal approach which is likely to include treatments to decrease pruritus as well as allergen identification, avoidance where possible and improving skin and coat hygiene.”

Sporimune is a 50 mg/ml oral solution administered by syringe, which is graduated to show both bodyweight and ml. It is being introduced to veterinary professionals within Dechra's Partners in Practice programme which aims to support vets and vet nurses as they diagnose, control and maintain complex dermatological conditions.

Mr Brown added: “It is critical that owners are fully involved and educated about their pet's condition for dogs to be treated effectively. So we have also developed support materials around the use of Sporimune for practices, including client information leaflets and a video on how to use the dosing syringe.”

Sporimune is now available from veterinary wholesalers. For further information visit www.dechra.co.uk/sporimune.